Biblio Discovery — Demo Discovery Service

24 results for "Pascal Hammel"

Showing 1–20 · 2.29 seconds · RSS

  1. Journal Article

    A novel event-free survival endpoint in locally advanced pancreatic cancer

    Pascal Hammel; Ewa Carrier; Mairead Carney et al.

    Therapeutic Advances in Medical Oncology, Vol. 13 · 2021 · English · DOAJ Scopus

    The treatment paradigm for locally advanced pancreatic cancer (LAPC) is evolving rapidly. The development of neoadjuvant therapies composed of combination therapies and the evaluation of their impact on conversion to borderline resectable (BR) status, resection, and ultimately overall survival (OS)…

  2. Journal Article

    Prolonged Survival in a Patient with Neuroendocrine Tumor of the Cecum and Diffuse Peritoneal Carcinomatosis

    Louis de Mestier; Cindy Neuzillet; Olivia Hentic et al.

    Case Reports in Gastroenterology, Vol. 6 No. 1 · 2012 · English · DOAJ Scopus

    Peritoneal carcinomatosis is a well-known factor of poor prognosis in patients with digestive adenocarcinomas. Peritoneal dissemination may also occur in midgut well-differentiated neuroendocrine tumors, but its influence on survival is ill-defined. We report here the history of a 64-year-old woman…

  3. Journal Article

    Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake

    Talia Golan; Raffaella Casolino; Andrew V. Biankin et al.

    Therapeutic Advances in Medical Oncology, Vol. 15 · 2023 · English · DOAJ Scopus

    Prognosis is generally poor for patients with pancreatic ductal adenocarcinoma. However, patients with germline BRCA1 or BRCA2 mutations (gBRCAm) may benefit from first-line platinum-based chemotherapy and maintenance therapy with the poly(adenosine diphosphate-ribose) polymerase inhibitor olaparib…

  4. Journal Article

    Fatal Bile Duct Necrosis: A Rare Complication of Transcatheter Arterial Chemoembolization in a Patient with Endocrine Hepatic Metastasis

    Anne-Laure Pelletier; Pascal Hammel; Magali Zappa et al.

    Case Reports in Gastroenterology, Vol. 2 No. 3 · 2008 · English · DOAJ Scopus

    We report the first case of fatal bile duct necrosis following transcatheter arterial chemoembolization (TACE) in a 58-year-old woman. The patient underwent two TACEs to treat hepatic metastases from an ileal endocrine tumor. Persistent cholestasis occurred after the second procedure, leading to…

  5. Journal Article

    Multicentre, interventional, single-arm study protocol of telemonitored circadian rhythms and patient-reported outcomes for improving mFOLFIRINOX safety in patients with pancreatic cancer (MultiDom, NCT04263948)

    Pascal Hammel; Rene Adam; Francis Levi et al.

    BMJ Open, Vol. 13 No. 6 · 2023 · English · DOAJ Scopus

    Introduction Circadian clocks regulate cellular proliferation and drug effects. Tolerability and/or efficacy of anticancer therapies have been improved by their administration according to circadian rhythms, while being predicted by circadian robustness. The combination of leucovorin, fluorouracil…

  6. Journal Article

    Management of esogastric cancer in older patients

    Thomas Aparicio; Anna Carteaux-Taieb; Amélie Arégui et al.

    Therapeutic Advances in Medical Oncology, Vol. 16 · 2024 · English · DOAJ Scopus

    Although esogastric cancers often affect patients over 75, there are no specific age-related guidelines for the care of these patients. Esogastric cancers have a poor prognosis and require multimodal treatment to obtain a cure. The morbidity and mortality of these multimodal treatments can be…

  7. Journal Article

    Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies

    Anthony Turpin; Cindy Neuzillet; Elise Colle et al.

    Therapeutic Advances in Medical Oncology, Vol. 14 · 2022 · English · DOAJ Scopus

    Mortality from pancreatic ductal adenocarcinoma (PDAC) is increasing worldwide and effective new treatments are urgently needed. The current treatment of metastatic PDAC in fit patients is based on two chemotherapy combinations (FOLFIRINOX and gemcitabine plus nab-paclitaxel) which were validated…

  8. Journal Article

    Time interval from last visit to imaging diagnosis influences outcome in pancreatic adenocarcinoma: A regional population-based study on linked medico-administrative and clinical data

    Vittoria Balzano; Emeline Laurent; Aline-Marie Florence et al.

    Therapeutic Advances in Medical Oncology, Vol. 14 · 2022 · English · DOAJ Scopus

    Background: Excessive waiting time intervals for the diagnosis and treatment of patients with pancreatic cancer can influence their prognosis but they remain unclear. The objective was to describe time intervals from the medical visit to diagnostic imaging and to treatment and their prognostic…

  9. Journal Article

    Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors

    Pascal Hammel; Carole Vitellius; Émeric Boisteau et al.

    Therapeutic Advances in Medical Oncology, Vol. 12 · 2020 · English · DOAJ Scopus

    Metastatic pancreatic ductal adenocarcinomas (PDACs) are now more effectively controlled using chemotherapy combinations such as FOLFIRINOX and gemcitabine plus nab-paclitaxel (NabP) regimens with a subset of patients who achieve a sustained tumor stabilization or response. The next challenge is to…

  10. Journal Article

    Muscle Loss During First‐Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity

    Pauline Parent; Frédéric Pigneur; Marc Hilmi et al.

    Journal of Cachexia, Sarcopenia and Muscle, Vol. 16 No. 1 · 2025 · English · DOAJ Scopus

    ABSTRACT Background Advanced pancreatic ductal adenocarcinoma (aPDAC) is often accompanied by significant muscle mass loss, contributing to poor prognosis. SarcAPACaP, an ancillary study of the GERCOR‐APACaP phase III trial, evaluated the role of adapted physical activity (APA) in aPDAC Western…

  11. Journal Article

    Ovarian metastases of pancreatic adenocarcinoma: clinical presentation, role of surgery, and potential value of the mutational profile for the differential diagnosis with primary mucinous ovarian carcinoma

    Alice de Malet; Magali Svrcek; Anne Kerbaol et al.

    Therapeutic Advances in Medical Oncology, Vol. 13 · 2021 · English · DOAJ Scopus

    Background: Ovarian metastases (OM) of pancreatic adenocarcinoma (PA) (OM-PA) can mimic primary ovarian mucinous carcinoma (POMC) on imaging and histology. These metastases are often symptomatic and not highly chemosensitive, so that oophorectomy may be considered. Aims: The aims of this study were…

  12. Journal Article

    Potential barriers to performing adapted physical activity in patients with digestive cancer: results of the prospective observational APACADIG study

    Clémence Trihan; Cindy Richard; Emeric Boisteau et al.

    Therapeutic Advances in Medical Oncology, Vol. 17 · 2025 · English · DOAJ Scopus

    Background: Adapted physical activity (APA) is key supportive care in cancer patients. Very few studies have evaluated APA in digestive cancers, and the eligibility and feasibility of an APA program in this population have not been clearly defined. Objectives: Primary objective: to analyze the…

  13. Journal Article

    Efficacy and tolerance of LV5FU2-carboplatin chemotherapy in patients with advanced pancreatic ductal adenocarcinoma after failure of standard regimens

    Thomas Chaigneau; Lina Aguilera Munoz; Caroline Oger et al.

    Therapeutic Advances in Medical Oncology, Vol. 15 · 2023 · English · DOAJ Scopus

    Background: Chemotherapy options in patients with advanced pancreatic ductal adenocarcinoma (PDAC) after failure of standard chemotherapies are limited. Objectives: We aimed to report the efficacy and safety of the leucovorin and 5-fluorouracil (LV5FU2) and carboplatin combination in this setting…

  14. Journal Article

    Identification of a large intra-exonic deletion in exon 18 in a pancreatic ductal adenocarcinoma

    Inès Debbabi; Sophie Vacher; Cindy Neuzillet et al.

    Therapeutic Advances in Medical Oncology, Vol. 15 · 2023 · English · DOAJ Scopus

    By 2030, pancreatic cancer will become the second leading cause of cancer-related deaths in the United States and in Europe. The management of patients with advanced pancreatic cancer relies on chemotherapy and poly (ADP-ribose) polymerase inhibitors for patients who carry BRCA1/2 inactivating…

  15. Journal Article Full text

    Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

    Hedy Lee Kindler; Pascal Hammel; Michele Reni et al.

    Journal of Clinical Oncology · 2022 · English · OpenAlex Scopus

    PURPOSE The phase III POLO study demonstrated significant progression-free survival (PFS) benefit for active olaparib maintenance therapy versus placebo for patients with metastatic pancreatic adenocarcinoma and a germline BRCA mutation. Here, we report the final analysis of overall survival (OS)…

  16. Journal Article

    Diagnosis and treatment of bacterial peritonitis in patients with gastrointestinal cancer: an observational multicenter study

    Alix Riescher-Tuczkiewicz; Jules Grégory; Frederic Bert et al.

    Therapeutic Advances in Medical Oncology, Vol. 16 · 2024 · English · DOAJ Scopus

    Background: Bacterial peritonitis (BP) in patients with gastrointestinal (GI) cancer has been poorly described, and its prevalence is unknown. Objectives: This study aimed to evaluate in patients with both GI cancer and ascites the prevalence of BP, associated features, mechanisms, prognosis, and…

  17. Journal Article

    SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumors

    Pascal Hammel; Denis Smith; Pauline Afchain et al.

    Therapeutic Advances in Medical Oncology, Vol. 16 · 2024 · English · DOAJ Scopus

    Background: Sunitinib, a multitarget tyrosine kinase inhibitor, showed encouraging antitumor activity and manageable toxicity in patients with advanced midgut neuroendocrine tumors (NETs) in earlier results from phase I and II trials. Patients and methods: In this phase II trial, patients with a…

  18. Journal Article

    Impact on health‐related quality of life deterioration‐free survival of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial

    Emilie Charton; Jean‐Baptiste Bachet; Pascal Hammel et al.

    Cancer Medicine, Vol. 8 No. 11 · 2019 · English · DOAJ Scopus

    Abstract Background The phase II AFUGEM GERCOR trial aimed to assess the efficacy of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine (gemcitabine group) or simplified leucovorin and fluorouracil (sLV5FU2 group) in patients with previously untreated metastatic pancreatic…

  19. Journal Article

    Mapping National Definitions, Classifications, and Policy Approaches to Poor-Prognosis Cancers Across the G7 Cancer Initiative Countries

    Marisa Nishio; Hiromi Sugiyama; Valerie McCormack et al.

    JCO Global Oncology, Vol. 12 No. 4 · 2026 · English · DOAJ Scopus

    PURPOSEIn 2023, the G7 Cancer Initiative was launched by Australia, Canada, France, Germany, Japan, the United Kingdom, and the United States with the aim of enhancing global cancer control, and with poor-prognosis cancers as a priority. To facilitate effective collaboration among G7 Cancer, we…